Head and Neck Cancer Registry (LORHAN)

Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada

NCT02705833 ·Status: COMPLETED

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

NCT06211335 ·Status: RECRUITING ·Phase: PHASE1

Discovering Factors in Head and Neck Cancer Patients' Clinical Study Experiences

NCT05801770 ·Status: NOT_YET_RECRUITING

Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00513435 ·Status: COMPLETED ·Phase: PHASE2

Ii-HANC Improving Incurable Head and Neck Cancer Healthcare Experiences

NCT05714436 ·Status: COMPLETED

A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma

NCT06894459 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Multicenter Phase II Study of Sentinel Node Detection in Squamous Cell Carcinoma T1-T2N0 of the Oropharynx Treated With Radiotherapy and Larynx Treated by Surgery, Laser or Robot

NCT03010553 ·Status: UNKNOWN ·Phase: PHASE2

Dose De-escalation and Sentinel LN Mapping Driven Radiotherapy of Contralateral Neck in Ipsilateral Node Positive HNSCC

NCT04688528 ·Status: RECRUITING ·Phase: NA

Nicotine Levels With Response Rates to Radiation Alone or With Chemo In Head & Neck Cancer

NCT01084733 ·Status: COMPLETED

Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer

NCT02388932 ·Status: TERMINATED ·Phase: NA

Low-Dose Weekly vs High-Dose Cisplatin

NCT03649048 ·Status: RECRUITING ·Phase: NA

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT02207530 ·Status: COMPLETED ·Phase: PHASE2

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

NCT00004070 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

NCT06494995 ·Status: RECRUITING ·Phase: PHASE2

Patient-Reported Outcomes in Head and Neck Cancer

NCT03918382 ·Status: RECRUITING ·Phase: NA

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

NCT00494182 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer

NCT00014118 ·Status: COMPLETED ·Phase: PHASE2

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

NCT01267240 ·Status: TERMINATED ·Phase: PHASE2

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT01349933 ·Status: COMPLETED ·Phase: PHASE2

A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma

NCT01046266 ·Status: COMPLETED ·Phase: PHASE1

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

NCT04333537 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

NCT01345682 ·Status: COMPLETED ·Phase: PHASE3

S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00096512 ·Status: COMPLETED ·Phase: PHASE2

Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

NCT01465815 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT04831450 ·Status: WITHDRAWN ·Phase: PHASE2